Intrommune Therapeutics, Inc., a clinical stage biotechnology company, has successfully completed the final visit of the last patient in the Phase 1 OMEGA Clinical Study for individuals with peanut allergy. This 48-week trial is specifically designed for adults with peanut allergies and aims to gather long-term safety data while determining the appropriate starting dose for INT301, an innovative..
IntelGenx Corp. has recently announced a groundbreaking research collaboration with Karolinska University Hospital. The focus of this collaboration is to explore the potential of using Montelukast VersaFilm® as a treatment for Parkinson's Disease. Led by the esteemed Professor Per Svenningsson, an expert in clinical neuroscience, this study will delve into the efficacy of IntelGenx's innovative ..
Grifols, a global leader in the production of plasma-derived medicines, has announced positive results from a Phase 4 study investigating the use of XEMBIFY®, its subcutaneous immunoglobulin product, administered every two weeks. The study successfully met its primary objective by demonstrating comparable levels of total immunoglobulins when compared to weekly administration in patients with pri..
The Phase 3 data of donanemab, a potential treatment for Alzheimer's disease, has been announced by the Alzheimer's Association. The data, presented at the Alzheimer's Association International Conference® (AAIC®) 2023 by Eli Lilly and Company, showcases promising advancements in Alzheimer's research and treatment.   In the TRAILBLAZER-ALZ 2 clinical trial, donanemab demonstrated its ability..
Leap Therapeutics, a biotechnology company specializing in targeted and immuno-oncology therapeutics, has announced the initiation of Part B of the DeFianCe study for DKN-01 in colorectal cancer patients. This study aims to assess the effectiveness of Leap's anti-Dickkopf-1 (DKK1) antibody, DKN-01, when combined with standard care bevacizumab and chemotherapy as a second-line treatment for advan..
16">The study aims to determine the effectiveness of SerpinPC in reducing bleeds in individuals with hemophilia B. Hemophilia B is a rare genetic disorder that affects the blood's ability to clot properly, leading to prolonged bleeding and increased risk of complications. Current treatment options for hemophilia B include regular infusions of clotting factors, but these can be costly and time-co..
Less than half of the new drug approvals are actually providing therapeutic value to patients, according to a recent study published in The BMJ. Despite the increasing number of drugs being approved in both the U.S. and Europe, it seems that many of them are not significantly improving patient outcomes. The study focused on 124 first indications that were approved by the FDA and European Medicin..
